Current status of molecularly targeted therapy for hepatocellular carcinoma: Clinical practice

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 242-255

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brivanib; Complete remission; Hepatocellular carcinoma; Molecular targeted agent; Sorafenib; Sunitinib

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ARQ 197; AVE 1642; BELINOSTAT; BEVACIZUMAB; BIIB 022; BRIVANIB; CECUXIMAB; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; LAPATINIB; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NIK 333; PHOSPHOTRANSFERASE INHIBITOR; PI 88; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB; TAC 101; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACNE; ANOREXIA; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; WOUND INFECTION; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77955715213     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0089-y     Document Type: Review

References (62)

1. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687
2. Minguez B, Tovar V, Chiang D et al (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 25:186-194
3. Villanueva A, Newell P, Chiang DY et al (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55-76
4. Laurent-Puig P, Zucman-Rossi J (2006) Genetics of hepatocellular tumors. Oncogene 25:3778-3786
5. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327
6. Hopfner M, Shuppan D, Scherubl H (2008) Growth factor receptors and related signaling pathways as target for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1-14
7. Campbell JS, Hughes SD, Gilbertson DG et al (2005) Plateletderived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci 102:3389-3394
8. Ogasawara S, Yano H, Iemura A et al (1996) Expression of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 24:198-205
9. Kudo M (2008) Hepatocellular carcinoma 2009 and beyond: from the surveillance tomolecular targeted therapy.Oncology 75:S1-S12
10. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen- activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310
11. Schmidt CM, McKillop IH, Cahill PA et al (1997) Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236:54-58
12. Huynh H, Nguen TTT, Chow KHP et al (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)- MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterology 3:19-30
13. Calvisi DF, Ladu S, Gorden A et al (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117-1128
14. Bos JL (1989) ras Oncogenes in human cancer: review. Cancer Res 49:4682-4689
15. Beeram M, Patnaik A, Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23:6771-6790
16. Tannapfel A, Sommerer F, Benicke M et al (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712 (Pubitemid 36528874)
17. Jenke HS, Deml E, Oesterle D (1994) C-raf expression in early ratliver tumorigenesis after promotion with polychlorinated biphenyls or Phenobarbital. Xenobiotica 24:569-580
18. Beer DG, Neveu MJ, Paul DL et al (1998) Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms. Cancer Res 48:1610-1617
19. Hwang YH, Choi JY, Kim S et al (2004) Over-expression c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29:113-121
20. Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
21. Ohren JF, Chen H, Pavlovsky A et al (2004) Structures of human MAP kinase kinase 1(MEK1) and MEK2 describe novel non competitive kinase inhibition. Nat Struct Mol Biol 11:1192-1197
22. Huynh H, Nguyen TTT, Chow KHP et al (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)- MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19-40
23. Engelma J (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562
24. Zhou L, Huang Y, Li J et al (2009) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (Epub ahead of print)
25. Chen J, Wang Q, Fu X et al (2009) Involvement of PI3K/PTEN/ AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 39:177-186
26. Villanueva A, Chiang DY, Newell P et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972-1983
27. Treiber G (2009) mTOR inhibitors for hepatocellular carcinoma: a forward-moving target. Expert Rev Anticancer Ther 9:247-261
28. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
29. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-268
30. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to antiangiogenic therapeutics? Nat Rev Cancer 8:880-887
31. Fernandez M, Semela D, Bruix J et al (2009) Angiogenesis in liver disease. J Hepatol 50:604-620
32. Schoenleber SJ, Kurtzl DM, Talwalkar JA et al (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100:1385-1392
33. Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of Sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicenter, phase II study. Lancet Oncol 10:794-800
34. Zhu AX, Sahani DV, Duda DG et al (2009) Efficacy, safety, and potential biomarker of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027-3035
35. Forner A, Llovet JM, Bruix J (2009) Sunitinib and the benefits of a negative study. Lancet Oncol 10:743-744
36. Raoul JL, Flinn RS, Kang YK et al (2009) An open-label phase II study of first- and second-line treatment with Brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 27:15S Suppl; Abstr 4577
37. Kanai F, Yoshida H, Tateishi R et al (2008) Final results of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. J Clin Oncol 26 (abstract 4589)
38. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
39. Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129:245-251
40. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663
41. Thomas MB, Chadhal R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1066
42. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and Erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850
43. Modified folfox7/bevacizumab or modified Xelox/bevacizumab with or without erlotinib in first-line metastatic colorectal cancer (MCRC): results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). J Clinical Oncol, 2007 ASCO Annual Meeting Proceedings Part I, vol 25, No. 18S: 4097
44. Tournigand B, Samson W, Scheithauer C et al (2009) mFOLFOX- bevacizumab or XELOX-bevacizumab then bevacizumab alone or with erlotinib in first-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety analysis of DREAM study. J Clin Oncol 27:15S, ASCO Annual Meeting Abstract No:4077C
45. Hecht JR, Mitchell E, Chidiac T et al (2008) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680
46. Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapywith sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714
47. Burris HA III, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313
48. Bekaii-Saab T, Markowitz J, Prescott N et al (2009) A multiinstitutional phase II study of the efficacy and tolerability of Lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 15:5895-5901
49. Zhu AX, Stuart K, Blaszkowsky LS et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581-589
50. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Dis 7:501-516
51. Scharf JG, Braulke T (2003) The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35:685-693
52. Chen YW, Boyartchuk V, Lewis BC (2009) Differential roles of insulin-like growth factor receptor-and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia 11:835-845
53. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
54. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
55. Kudo M (2010) Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma in Japan, including its impact on complete remission. Oncology (in press)
56. Okita K, Imanaka K, Chiba N et al (2010) Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization. ASCO Gastrointestinal Cancers Symposium Proceedings 2010: 89 (LBA128)
57. Murata K, Suzuki H, Okano H et al (2010) Hypoxia-induced desc- carboxy prothrombin production in hepatocellular carcinoma. Int J Clin Oncol 36:161-170
58. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300
59. Toh H, Chen PJ, Carr BI et al (2009) A phase II study of ABT- 869 in hepatocellular carcinoma (HCC) : Interim analysis. J Clin Oncol 27:15s (Suppl; Abstr 4581)
60. Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992-2998
61. O'Dwyer PJ, Giantonio BJ, Levy DE et al (2006) Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 24:18S (Suppl, Abstr 4143)
62. Ramanathan RK, Belani CP, Singh DA et al (2009) A phase II study of Lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777-783